#888 Real-world treatment patterns in recurrent or advanced endometrial cancer patients who initiated first-line systemic therapy in 5 European countries: a retrospective chart review study
Gardado en:
| Publicado en: | International Journal of Gynecological Cancer vol. 33, no. Suppl 3 (Sep 2023), p. A186 |
|---|---|
| Autor Principal: | |
| Outros autores: | , , , , |
| Publicado: |
Elsevier Limited
|
| Materias: | |
| Acceso en liña: | Citation/Abstract |
| Etiquetas: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 2869209734 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1048-891X | ||
| 022 | |a 1525-1438 | ||
| 024 | 7 | |a 10.1136/ijgc-2023-ESGO.383 |2 doi | |
| 035 | |a 2869209734 | ||
| 045 | 2 | |b d20230901 |b d20230930 | |
| 100 | 1 | |a Kelkar, Sneha S | |
| 245 | 1 | |a #888 Real-world treatment patterns in recurrent or advanced endometrial cancer patients who initiated first-line systemic therapy in 5 European countries: a retrospective chart review study | |
| 260 | |b Elsevier Limited |c Sep 2023 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Introduction/BackgroundNovel therapies are being investigated for first-line use in recurrent or advanced endometrial cancer (aEC) patients in Europe, however, country-specific real-world treatment patterns with conventional treatments are not well documented.MethodologyEndometrial Cancer Health Outcomes-Europe-First-Line (ECHO-EU-1L) is a retrospective chart review study in recurrent or aEC patients in United Kingdom (UK), France (FR), Germany (GE), Italy (IT), and Spain (SP). Physicians extracted de-identified data from medical records of adult female patients initiating first-line therapy between 1/JUL/2016 and 31/MAR/2020 after aEC diagnosis. Ethics approval and informed consent waivers were obtained.ResultsOverall, 57 physicians provided data for 242 patients (UK=49, FR=49, GE=48, IT=48, SP=48) with a median age of 69 years at aEC diagnosis, 49.2% with endometroid carcinoma, and 23.6% with ECOG≥2 at treatment start. Carboplatin-paclitaxel was the most prescribed first-line regimen in all countries (UK=51.0%, FR=79.6%, GE=58.3%, IT=66.7%, SP=81.3%). Second preference varied: cisplatin-paclitaxel in UK (28.6%), cisplatin-5-fluorouracil in FR (6.1%), bevacizumab-carboplatin-paclitaxel in GE (18.8%), carboplatin monotherapy in IT (12.5%), and doxorubicin-liposomal, megestrol acetate, or paclitaxel in SP (4.2% each). Overall, physicians prescribed >20 different regimens in first-line. Overall, 95% of patients discontinued first-line treatment, mostly due to progression (cross-country range: 40.0–59.2%), regimen completion (26.7–49.0%), and maximum clinical benefit reached (6.1–35.6%). Median time to discontinuation was 5.2 months (95% confidence interval: 4.9–5.5) (UK=4.3, FR=5.4, GE=5.5, IT=6.3, SP=5.3). Overall, 31.3–54.2% of patients initiated second-line treatment.ConclusionIn European recurrent or aEC patients prior to 2021, guideline-recommended carboplatin-paclitaxel was a prevalent first-line regimen, however there were marked cross-country variations in other regimens selected and overall treatment approach. Novel therapies are needed to help streamline treatment options for these patients.DisclosuresFunding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Eisai Inc., Nutley, NJ, USA. Sneha Kelkar and Yoscar Ogando are employees of OPEN Health, Bethesda, MD, USA, who were paid consultants of Merck Sharp & Dohme LLC a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. in connection with the development of this abstract, study design, management, and statistical analysis for the study. Vimalanand Prabhu and spouse are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and shareholder of Merck & Co., Inc., Rahway, NJ, USA. Jingchuan Zhang is an employee of Eisai Inc., Nutley, NJ, USA. Véronique Grall is an employee of M3 (EU), Abingdon, England, a subcontractor to OPEN Health, who were paid consultants of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA in the data collection for the study. Christian Marth is an employee of Medical University Innsbruck, Innsbruck, Austria, which has received funding for clinical research support from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and reports honoraria/consulting fees from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. | |
| 610 | 4 | |a Merck & Co Inc Merck Sharp & Dohme | |
| 651 | 4 | |a United States--US | |
| 651 | 4 | |a United Kingdom--UK | |
| 651 | 4 | |a Europe | |
| 653 | |a Endometrial cancer | ||
| 653 | |a Cancer therapies | ||
| 653 | |a Employees | ||
| 653 | |a Monoclonal antibodies | ||
| 653 | |a Physicians | ||
| 700 | 1 | |a Prabhu, Vimalanand S | |
| 700 | 1 | |a Zhang, Jingchuan | |
| 700 | 1 | |a Ogando, Yoscar M | |
| 700 | 1 | |a Grall, Véronique | |
| 700 | 1 | |a Marth, Christian | |
| 773 | 0 | |t International Journal of Gynecological Cancer |g vol. 33, no. Suppl 3 (Sep 2023), p. A186 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/2869209734/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |